Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design

Stensrud, Gry; Sande, Sverre Arne; Kristensen, Solveig; Smistad, Gro

doi:10.1016/s0378-5173(00)00338-0

Cited by 63 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of PQ encapsulation depended on the lipids that composed the vesicles and, consequently, on liposome charge and presence of cholesterol, on the buffer internal capacity and on the drug-to-lipid ratio and/or incubation time [34].…”

Section: Terminal Prophylaxis or Partmentioning

confidence: 99%

Primaquine revisited six decades after its discovery

Vale¹,

Moreira²,

Gomes³

2009

European Journal of Medicinal Chemistry

322

308

View full text Add to dashboard Cite

Section: Terminal Prophylaxis or Partmentioning

confidence: 99%

Primaquine revisited six decades after its discovery

Vale¹,

Moreira²,

Gomes³

2009

European Journal of Medicinal Chemistry

322

308

View full text Add to dashboard Cite

“…However, animal studies, especially 65 when using higher species, are associated with ethical issues and 66 costs of maintaining animal facilities can be high. If luminal perfor- 67 mance is to be evaluated directly in the gut, experimental costs can 68 also be high. In addition, in many cases the information collected 69 cannot be extrapolated to humans on a 1:1 basis.…”

mentioning

confidence: 99%

In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media

Markopoulos

Andreas

Vertzoni

et al. 2015

European Journal of Pharmaceutics and Biopharmaceutics

176

133

View full text Add to dashboard Cite

“…To improve the treatment efficacy and reduce the side effects of existing therapy, some dosage systems have been investigated, including liposomes [9], nanoparticles [10,11], microparticles [12], carrier proteins [13], injectable systems [14], and transdermal therapeutic systems [15 -17].…”

mentioning

confidence: 99%

Swelling, Erosion, and Release Behavior of PEO/Primaquine Matrix Tablets

et al. 2008

View full text Add to dashboard Cite

Extended-release primaquine tablets were developed using polyethylene oxide (PEO) as a hydrophilic swellable polymer with different amounts and molecular weights (4´10 6 and 8´10 6 ). Investigations were carried out in order to verify the matrix performance. The evaluated parameters were weight, hardness, thickness, friability, and drug content. The swelling and erosion matrices as well as drug release profile were analyzed under dissolution conditions. The statistical model ANOVA and Tukey-Kramer HSD were considered. The results showed that all formulations provided adequate physical characteristics and a time release about eight hours following a non-Fickian diffusion model. The kinetics of drug delivery was directly related to the synchronization of swelling and erosion matrices. The formulations prepared with high PEO concentrations showed a lower rate of erosion, a slower drug release, and faster rate of swelling, as compared with matrices containing lower PEO concentration.

show abstract

Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design

Cited by 63 publications

References 26 publications

Primaquine revisited six decades after its discovery

Primaquine revisited six decades after its discovery

In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media

Swelling, Erosion, and Release Behavior of PEO/Primaquine Matrix Tablets

Contact Info

Product

Resources

About